Tarceva — Medica
Non-Small Cell Lung Cancer (NSCLC)
Initial criteria
- age ≥ 18 years
- advanced or metastatic disease
- EGFR mutation-positive non-small cell lung cancer as detected by an approved test (examples include exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X, and S768I)
Approval duration
1 year